Last update 21 Nov 2024

Anti-p53 T-cell receptor-transduced PBL(NCI)

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms-
Target-
Mechanism
Cell replacements
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases
Active Indication-
Inactive Indication
Kidney NeoplasmsMelanoma, Cutaneous MalignantNeoplasm Metastasis
Originator Organization
National Cancer InstituteNational Cancer Institute
Active Organization-
Inactive Organization
National Institutes of Health Clinical Center
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-p53 T-cell receptor-transduced PBL(NCI)
NCT00704938 / TerminatedPhase 2IIT
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination
100 Clinical Results associated with Anti-p53 T-cell receptor-transduced PBL(NCI)
Login to view more data
100 Translational Medicine associated with Anti-p53 T-cell receptor-transduced PBL(NCI)
Login to view more data
100 Patents (Medical) associated with Anti-p53 T-cell receptor-transduced PBL(NCI)
Login to view more data
100 Deals associated with Anti-p53 T-cell receptor-transduced PBL(NCI)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Kidney NeoplasmsPhase 2
US
National Institutes of Health Clinical Center
01 Jun 2008
Melanoma, Cutaneous MalignantPhase 2
US
National Institutes of Health Clinical Center
01 Jun 2008
Neoplasm MetastasisPhase 2
US
National Institutes of Health Clinical Center
01 Jun 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00704938 (CTgov)
Phase 2
Melanoma, Cutaneous Malignant | Neoplasm Metastasis | Kidney Neoplasms
3
(Anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC)
rguhpnrtai(hrhidafbvs) = lrwzqvnyqd afisicwzxj (onsnfzqbxr, kuoppyhxka - lbymiuecjl)
View more
-
14 Aug 2012
(Anti-p53 TCR PBL + DC + IL-2: Other Histology)
rguhpnrtai(hrhidafbvs) = uqrmhiabse afisicwzxj (onsnfzqbxr, cmwfzvytqc - ffiqkwxfry)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free